





RealRate

# PHARMACEUTICAL 2018

ImmunoGen Inc.  
Rank 150 of 349

immu•gen

The relative strengths and weaknesses of ImmunoGen Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ImmunoGen Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 134% points. The greatest weakness of ImmunoGen Inc. is the variable Other Liabilities, reducing the Economic Capital Ratio by 43% points.

The company's Economic Capital Ratio, given in the ranking table, is -135%, being 143% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	276,341
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	55,770
Liabilities, Non-Current	4,236
Other Assets	3,797
Other Compr. Net Income	0
Other Expenses	40,416
Other Liabilities	252,565
Other Net Income	2,607
Property and Equipment	14,538
Research and Development	139,739
Revenues	115,447
Selling, General and Administrative Expense	33,911

Output Variable	Value in 1000 USD
Assets	294,676
Liabilities	312,571
Expenses	214,066
Stockholders Equity	-17,895
Net Income	-96,012
Comprehensive Net Income	-96,012
Economic Capital Ratio	-135%



RealRate

• Financial Strength Rankings using Artificial Intelligence

• [www.realrate.ai](http://www.realrate.ai)